Siemens Healthineers Q2 Beats As Diagnostic Imaging Recovery Hits Inflection

Siemens Healthineers reported fiscal second-quarter results materially ahead of consensus, with revenue of €5.7 billion up 6.8% year-on-year on a like-for-like basis and the Imaging segment specifically posting its strongest quarter in three years as the long-awaited recovery in hospital-side capital-equipment ordering finally hit a clear inflection.

The Imaging segment growth — which the company runs as a meaningful proxy for the global hospital-system equipment-spending cycle — was 9.4% on a comparable basis, with order-book entries growing meaningfully faster than revenue. The book-to-bill ratio of 1.18 confirms the order-pipeline visibility that has been firming since late 2025 has now translated into the quarterly revenue numbers, with management raising the full-year segment guidance for both revenue growth and adjusted-margin against the previous range.

The Diagnostics business — which had been the more challenged segment through the past two cycles — also delivered a notably better quarter, with the molecular-diagnostics franchise specifically benefiting from continued recovery in non-COVID test volumes and the in-vitro diagnostics product line returning to growth for the first time in five quarters. The Varian radiation-oncology subsidiary continued its steady mid-single-digit growth trajectory, with the proton-therapy programme contributing a particularly strong quarter from a small base.

The Advanced Therapies segment delivered the headline-fastest growth across the group at 11.4% year-on-year, with the cardiology-imaging product line and the interventional radiology business both contributing meaningfully. The increasing share of Advanced Therapies within the consolidated segment-revenue mix is a structural-margin tailwind for the group as a whole, given the materially-higher-margin profile of the segment relative to the historical Imaging-and-Diagnostics core.

For the wider health-tech sector, the Siemens Healthineers print provides a useful macro datapoint. Hospital capital-equipment ordering globally has been notably soft for two years, and the Q1 2026 order-book strength suggests the budget-environment for new equipment installations has now genuinely shifted. GE HealthCare's parallel results window through next week is the most-watched read-across; if the equivalent trends are visible in the GE numbers, the broader cyclical recovery thesis for the global imaging-and-diagnostics segment will be substantially confirmed.